Drug Trial Radar · NCT02558296
Bexagliflozin Efficacy and Safety Trial
Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,700
Actual
Start
Oct 2015
Primary completion
Aug 2018
Study completion Oct 23, 2019
Sponsor
- Lead sponsor
- TheracosIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.
Conditions
- Type 2 Diabetes Mellitus
Interventions
BexagliflozinDrug
20 mg, tablet
PlaceboDrug
20 mg tablet to match active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c From Baseline to Week 24Time frame: 24 weeks
Locations
157 sites in 10 countries. Site status is shown where the registry gives one.
Research Site 1090
Gilbert, Arizona
Research Site 1041
Little Rock, Arkansas
Research Site 1073
Azusa, California
Research Site 1076
Concord, California
Research Site 1078
Fresno, California
Research Site 1089
Harbor City, California
Research Site 1058
Lincoln, California
Research Site 1051
Los Angeles, California
Research Site 1004
Los Angeles, California
Research Site 1068
Montclair, California
Research Site 1077
Orange, California
Research Site 1218
Denver, Colorado
Research Site 1092
Golden, Colorado
Research Site 1216
Norwalk, Connecticut
Research Site 1083
Newark, Delaware
Research Site 1057
Boca Raton, Florida
Research Site 1059
Brooksville, Florida
Research Site 1050
Panama City, Florida
Research Site 1099
Port Charlotte, Florida
Research Site 1066
Tampa, Florida
Research Site 1072
Augusta, Georgia
Research Site 1082
Pocatello, Idaho
Research Site 1258
Champaign, Illinois
Research Site 1043
Anderson, Indiana
Research Site 1071
Avon, Indiana
Research Site 1086
Des Moines, Iowa
Research Site 1224
Covington, Kentucky
Research Site 1228
Annapolis, Maryland
Research Site 1221
Baltimore, Maryland
Research Site 1079
Hyattsville, Maryland
Research Site 1223
Midland, Michigan
Research Site 1217
Petoskey, Michigan
Research Site 1254
Ypsilanti, Michigan
Research Site 1054
St Louis, Missouri
Research Site 1060
St Louis, Missouri
Research Site 1252
Kalispell, Montana
Research Site 1052
Omaha, Nebraska
Research Site 1263
Omaha, Nebraska
Research Site 1080
Las Vegas, Nevada
Research Site 1219
Somerset, New Jersey
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.